The following is a summary of “Randomized Study Comparing Continuous Glucose Monitoring and Capillary Glucose Testing in Patients With Type 2 Diabetes After Hospital Discharge,” published in the March ...

What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

One of the company’s biggest growth engines has been its FreeStyle Libre franchise in the diabetes care segment, which includes a variety of continuous glucose monitoring (CGM) devices and has ...

A new randomised clinical trial – carried out by researchers at the University of Bath in the UK – found that a CGM sold by Abbott (the Freestyle Libre 2) "systemically overestimated" glucose ...

Abbott's ABT diversified business portfolio is well-positioned to drive momentum. However, the international business ...

Its most important segment, though, remains diabetes care where it markets the FreeStyle Libre, one of the leading franchises of continuous glucose monitoring (CGM) systems on the market.

Savefor later Page saved! You can go back to this later in your Diabetes and Me Close ...